Tirzepatide

Product Description Tirzepatide is a synthetic 39-amino acid linear peptide that acts as a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It features two Aib (α-aminoisobutyric acid) residues and a C20 fatty diacid moiety attached via a linker to lysine-20 for extended half-life. Supplied as ≥98% pure lyophilized powder (HPLC/MS verified), it is designed for laboratory studies on glucose metabolism, weight regulation, and incretin signaling pathways.

Key Research Mechanism Tirzepatide simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. This dual agonism promotes improved glycemic control, increased energy expenditure, and significant fat loss in research models while leveraging fatty acid acylation for prolonged activity.

Primary Research Areas

• Glucose homeostasis and type 2 diabetes models
• Weight management, appetite regulation, and obesity studies
• Incretin signaling, insulin sensitivity, and beta-cell function
• Metabolic syndrome, lipid metabolism, and cardiovascular research

Intended Use For in vitro and in vivo research only. Not for human or veterinary use. This product is sold strictly for scientific and laboratory investigation. Researchers must follow all institutional and regulatory guidelines. Not evaluated by the FDA.